IP Library Granted Patent US 10,414,756
Granted Patent B2
US 10,414,756 · App. 15/553,892 · Granted Sep 17, 2019

2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof

Inventors: Xiaoyun Zhu (Changzhou, CN); Mingyu Jiang (Changzhou, CN); Aining Ji (Changzhou, CN)
Assignee: NANJING DIANSU BIOLOGICAL TECHNOLOGY CO. LTD
C07D403/04A61K31/506C07B59/002C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,414,756
App. No.
15/553,892
Granted
Sep 17, 2019
Kind
B2
Abstract

Disclosed are a 2-(2,4,5-substituted aniline) pyrimidine derivative, a pharmaceutical composition and a use thereof. The pharmaceutical composition comprises a therapeutically effective amount of the 2-(2,4,5-substituted aniline) pyrimidine derivative, a solvate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Also disclosed is a use of the 2-(2,4,5-substituted aniline) pyrimidine derivative, a solvate, or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating cancers. The compounds of the present invention have a relatively high solubility in water and a relatively high permeability, and/or a relatively low binding ability to plasma proteins, and at the same time have a relatively low toxicity characteristic and a relatively high anti-tumor activity.

Claims (10)

1. A 2-(2,4,5-substituted aniline)pyrimidine derivative, solvate, or pharmaceutically acceptable salt thereof selected from the group consisting of

N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-(D 3 -methyl)indol-3-yl)pyrimidin-2-yl]amino}phenyl)-2-acrylamide;

N-(2-{2-dimethylaminoethyl-methylamino}-4-(D 3 -methoxy)-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)-2-acrylamide;

N-(2-{2-dimethylaminoethyl-(D 3 -methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)-2-acrylamide;

N-(2-{2-di(D 3 -methyl)aminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)-2-acrylamide; and

N-(2-{2-[methyl(D 3 -methyl)amino]ethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)-2-acrylamid,

wherein the D 3 -methyl or D 3 -methoxy substituents comprise deuterium at a percentage higher than the natural abundance of deuterium.

2. The 2-(2,4,5-substituted aniline)pyrimidine derivative, solvate, or pharmaceutically acceptable salt thereof according to claim 1 , wherein the pharmaceutically acceptable salt includes a salt of an inorganic acid and a salt of an organic acid; the salt of the inorganic acid being hydrochloride, hydrobromide, hydriodate, sulfate, phosphate, or a salt of hydrogen disulfide; the salt of the organic acid being p-toluene sulfonate, salicylate, tartrate, hydrogen tartrate, ascorbate, maleate, benzene sulfonate, fumarate, gluconate, glucuronate, formate, glutamate, mesylate, esylate, benzene sulfonate, lactate, oxalate, brosylate, carbonate, citrate, benzoate, malate or acetate.

3. A method for treating lung cancer in a subject in need thereof, the method comprising administering an effective amount of the 2-(2,4,5-substituted aniline)pyrimidine derivative, solvate, or pharmaceutically acceptable salt thereof according to claim 1 , to the subject.

4. The method according to claim 3 , wherein the lung cancer is non small-cell lung cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: CHANGZHOU RUNNOR BIOLOGICAL TECHNOLOGY CO., LTD
To: NANJING DIANSU BIOLOGICAL TECHNOLOGY CO., LTD
Reel/Frame 046788/0533 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2017
From: ZHU, XIAOYUN; JIANG, MINGYU; JI, AINING
To: CHANGZHOU RUNNOR BIOLOGICAL TECHNOLOGY CO., LTD
Reel/Frame 043407/0307 →
Priority Claims (1)
CN 2014 1 0401604 · Aug 15, 2014 · national
Continuity (1)
Related Publication 20180016258A1 · Jan 18, 2018